207 related articles for article (PubMed ID: 19966210)
21. Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma.
Rapoport AP; Aqui NA; Stadtmauer EA; Vogl DT; Fang HB; Cai L; Janofsky S; Chew A; Storek J; Akpek G; Badros A; Yanovich S; Tan MT; Veloso E; Pasetti MF; Cross A; Philip S; Murphy H; Bhagat R; Zheng Z; Milliron T; Cotte J; Cannon A; Levine BL; Vonderheide RH; June CH
Blood; 2011 Jan; 117(3):788-97. PubMed ID: 21030558
[TBL] [Abstract][Full Text] [Related]
22. Different role of circulating myeloid-derived suppressor cells in patients with multiple myeloma undergoing autologous stem cell transplantation.
Lee SE; Lim JY; Kim TW; Ryu DB; Park SS; Jeon YW; Yoon JH; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Cho SG; Kim DW; Lee JW; Min CK
J Immunother Cancer; 2019 Feb; 7(1):35. PubMed ID: 30732646
[TBL] [Abstract][Full Text] [Related]
23. Immunomodulation of early engrafted natural killer cells with interleukin-2 and interferon-alpha in autologous stem cell transplantation.
Porrata LF; Inwards DJ; Lacy MQ; Markovic SN
Bone Marrow Transplant; 2001 Oct; 28(7):673-80. PubMed ID: 11704790
[TBL] [Abstract][Full Text] [Related]
24. Double high-dose therapy for Hodgkin's disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation.
Stewart DA; Guo D; Glück S; Morris D; Chaudhry A; deMetz C; Klassen J; Brown CB; Russell JA
Bone Marrow Transplant; 2000 Aug; 26(4):383-8. PubMed ID: 10982284
[TBL] [Abstract][Full Text] [Related]
25. A Phase IIb, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation.
Hari P; Aljitawi OS; Arce-Lara C; Nath R; Callander N; Bhat G; Allen LF; Stockerl-Goldstein K
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2100-2105. PubMed ID: 26327631
[TBL] [Abstract][Full Text] [Related]
26. High-Dose Melphalan Plus Thiotepa as Conditioning Regimen before Second Autologous Stem Cell Transplantation for "De Novo" Multiple Myeloma Patients: A Phase II Study.
Musso M; Messina G; Marcacci G; Crescimanno A; Console G; Donnarumma D; Scalone R; Pinto A; Martino M
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1932-8. PubMed ID: 26099830
[TBL] [Abstract][Full Text] [Related]
27. Multiple Myeloma: The Role of Autologous Stem Cell Transplantation in the Era of Immunotherapy.
Rocchi S; Zannetti BA; Marconi G; Lanza F
Cells; 2024 May; 13(10):. PubMed ID: 38786075
[TBL] [Abstract][Full Text] [Related]
28. Phagocyte function decreases after high-dose treatment with melphalan and autologous stem cell transplantation in patients with multiple myeloma.
Wichert S; Pettersson Å; Hellmark T; Johansson Å; Hansson M
Exp Hematol; 2016 May; 44(5):342-351.e5. PubMed ID: 26774385
[TBL] [Abstract][Full Text] [Related]
29. The changing role of high dose melphalan with stem cell rescue in the treatment of newly diagnosed multiple myeloma in the era of modern therapies-back to the future!
Kazandjian D; Dew A; Hill E
Best Pract Res Clin Haematol; 2020 Mar; 33(1):101150. PubMed ID: 32139015
[TBL] [Abstract][Full Text] [Related]
30. The choice of multiple myeloma induction therapy affects the frequency and severity of oral mucositis after melphalan-based autologous stem cell transplantation.
Fleming S; Harrison SJ; Blombery P; Joyce T; Stokes K; Seymour JF; Prince HM; Ritchie D
Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):291-6. PubMed ID: 24629850
[TBL] [Abstract][Full Text] [Related]
31. Mobilization of peripheral blood stem cells with chemotherapy and cytokines in multiple myeloma.
Hénon PR; Becker M; Sovalat H; Eisenmann JC; Donatini B; Sklenar I
Stem Cells; 1995 Aug; 13 Suppl 2():148-55. PubMed ID: 8520504
[TBL] [Abstract][Full Text] [Related]
32. Inpatient mortality of patients with multiple myeloma and renal impairment undergoing autologous stem cell transplantation.
Mohyuddin GR; Abbasi S; Okoniewski M; McClune B; Abdallah AO; Ganguly S; McGuirk J; Shune L
Eur J Haematol; 2020 Nov; 105(5):571-577. PubMed ID: 32662224
[TBL] [Abstract][Full Text] [Related]
33. Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m2 of melphalan in multiple myeloma: results of a pilot study including biological aspects.
Rossi JF; Fegueux N; Lu ZY; Legouffe E; Exbrayat C; Bozonnat MC; Navarro R; Lopez E; Quittet P; Daures JP; Rouillé V; Kanouni T; Widjenes J; Klein B
Bone Marrow Transplant; 2005 Nov; 36(9):771-9. PubMed ID: 16113665
[TBL] [Abstract][Full Text] [Related]
34. Early recovery of aggressive cytotoxic cells and improved immune resurgence with post-transplant immunotherapy for multiple myeloma.
Meehan KR; Wu J; Bengtson E; Hill J; Ely P; Szczepiorkowski Z; Kendall M; Ernstoff MS
Bone Marrow Transplant; 2007 Jun; 39(11):695-703. PubMed ID: 17417660
[TBL] [Abstract][Full Text] [Related]
35. Clinicopathologic Features of Therapy-Related Myeloid Neoplasms in Patients with Myeloma in the Era of Novel Therapies.
Jelloul FZ; Quesada AE; Yang RK; Li S; Wang W; Xu J; Tang G; Yin CC; Fang H; El Hussein S; Khoury J; Bassett RL; Garcia-Manero G; Manasanch EE; Orlowski RZ; Qazilbash MH; Patel KP; Medeiros LJ; Lin P
Mod Pathol; 2023 Jun; 36(6):100166. PubMed ID: 36990279
[TBL] [Abstract][Full Text] [Related]
36. Regulatory T cells suppress myeloma-specific immunity during autologous stem cell mobilization and transplantation.
Takahashi S; Minnie SA; Ensbey KS; Schmidt CR; Sekiguchi T; Legg SRW; Zhang P; Koyama M; Olver SD; Collinge AD; Keshmiri S; Comstock ML; Varelias A; Green DJ; Hill GR
Blood; 2024 Apr; 143(16):1656-1669. PubMed ID: 38295333
[TBL] [Abstract][Full Text] [Related]
37. Cellular immunotherapy for plasma cell myeloma.
Garfall AL; Vogl DT; Weiss BM; Stadtmauer EA
Bone Marrow Transplant; 2013 Nov; 48(11):1377-86. PubMed ID: 23645169
[TBL] [Abstract][Full Text] [Related]
38. Impact of timing of stem cell return following high dose melphalan in multiple myeloma patients with renal impairment: a single center experience.
Nesr G; Shah R; Kyriakou C; Sive J; Popat R; Yong K; Wisniowski B; Xu K; Wechalekar A; Lee L; Ings S; Papanikolaou X; Mahmood S; Mcmillan A; Horder J; Newrick F; Marfil J; Ainley L; Asher S; Cheesman S; Rabin N
Leuk Lymphoma; 2023; 64(8):1465-1471. PubMed ID: 37259553
[TBL] [Abstract][Full Text] [Related]
39. Immune reconstitution after autologous hematopoietic stem cell transplantation in relation to underlying disease, type of high-dose therapy and infectious complications.
Steingrimsdottir H; Gruber A; Björkholm M; Svensson A; Hansson M
Haematologica; 2000 Aug; 85(8):832-8. PubMed ID: 10942930
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics of High-Dose Propylene Glycol-Free Melphalan in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation.
Dhakal B; D'Souza A; Lakshman A; Hamadani M; Chhabra S; Thompson R; Shah N; Pasquini M; Hari P
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1610-1614. PubMed ID: 29751116
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
